人工智能辅助胸膜间皮瘤体积疗效标准(ARTIMES)的开发与验证:一项回顾性多队列多中心研究
该回顾性多队列多中心研究基于自动肿瘤分割和生物学推导阈值,开发并验证了人工智能辅助体积疗效标准(ARTIMES)。
要点
- ARTIMES中位提前5周检测到疾病进展。
- ARTIMES无进展生存期与总生存期试验级相关性更强(R² 88% vs 6%)。
核心结论
- 基于ARTIMES的无进展生存期改善了预后分层,且较基于mRECIST的无进展生存期显示出更好的试验级总生存期替代性。
研究设计与样本
- 训练深度学习分割模型使用1176次标注CT扫描(由12名放射科医生和1名呼吸科医生标注),另补充100次阴性CT扫描。
- 内部测试使用LUME-MESO中来自独立国际医院的98次CT扫描;外部测试使用MEDUSA队列(101次CT扫描,放射科医生校正分割)及SAKK17/18(22次CT扫描)和芝加哥大学(15次CT扫描)的独立手动分割数据集。
- 进展阈值源自一线治疗前多次CT或一线治疗后仅接受支持治疗患者的611次CT扫描;部分缓解阈值源自读者间变异性(451次CT扫描)。
- ARTIMES在8项临床试验(4674次CT扫描;943例患者)中验证,并与mRECIST比较,采用时变Cox比例风险模型及试验级替代终点分析(R²和替代阈值效应)。
主要发现
- 内部测试DSC为94-95%,手动分割为71-80%;NSD分别为98%和81-93%。
- 基线AI衍生肿瘤体积独立预测总生存期,且优于T分期和WHO体能状态。
关键数值与推荐
- ARTIMES进展阈值基于一线治疗前多次CT或一线治疗后仅支持治疗患者的611次CT扫描推导。
- 部分缓解阈值基于读者间变异性(451次CT扫描)推导。
临床怎么用
- ARTIMES基于自动肿瘤分割和生物学推导阈值,可能促进胸膜间皮瘤更可靠的疗效评估。
- ARTIMES较mRECIST更早检测到进展并改善预后分层,有待前瞻性验证后用于临床。
- 基线AI衍生肿瘤体积可独立预测总生存期,优于T分期和WHO体能状态。
局限性
- 本研究为回顾性设计。
- ARTIMES需前瞻性验证后方可临床应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Response evaluation in pleural mesothelioma is challenging because its crescent growth pattern is poorly captured by diameter-based criteria. We aimed to develop and validate artificial intelligence (AI)-assisted volumetric response criteria (ARTIMES) based on automated tumour segmentation and biologically derived thresholds. METHODS: In this retrospective, multicentre study, we included 10 926 CT scans from 2080 patients from 14 cohorts. A subset totalling 1176 CT scans from routine care (Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital) and trial cohorts (INITIATE, NivoMes, PEMMELA, LUME-MESO, NVALT19, and MiST1 trials) was annotated by 12 radiologists and 1 pulmonologist, supplemented by 100 negative CT scans, to train a deep-learning segmentation model. Internal testing included 98 CT scans from independent international hospitals in LUME-MESO. External testing included data from the MEDUSA cohort (101 CT scans with radiologist-corrected segmentations) and two fully independent manual segmentation datasets from SAKK17/18 (22 CT scans) and the University of Chicago (15 CT scans). AI segmentations were evaluated through dice similarity coefficient (DSC) and normalised surface distance (NSD) at 3 mm. Progressive disease thresholds were derived using data from patients with multiple CT scans before first-line therapy or receiving only supportive care after first-line treatment (611 CT scans), and partial response thresholds from inter-reader variability (derived from 451 CT scans). ARTIMES was validated using data from eight clinical trials (4674 CT scans; 943 patients) and compared with modified Response Evaluation Criteria in Solid Tumors (mRECIST) using time-varying Cox proportional hazards models and trial-level surrogate endpoint analysis against overall survival using R2 and surrogate threshold effect. FINDINGS: DSC was 94-95% in internal testing and 71-80% with manual segmentations. NSD was 98% and 81-93%, respectively. ARTIMES demonstrated superior patient-level prognostic performance compared with mRECIST (concordance index 0·83 [95% CI 0·79-0·87] vs 0·73 [0·66-0·80]; p=0·023) and detected progression a median of 5 weeks earlier (124 days [95% CI 115-126] vs 162 days [138-167]; p<0·0001). At the trial level, ARTIMES-based progression-free survival showed stronger correlation with overall survival (R2 88% [95% CI 42-100]) than did mRECIST-based progression-free survival (R2 6% [0-97]) and demonstrated a surrogate threshold effect at a progression-free survival hazard ratio of less than 0·82; no threshold was observed for mRECIST. Baseline AI-derived tumour volume independently predicted overall survival and outperformed T stage and WHO performance status. INTERPRETATION: ARTIMES-based progression-free survival improves prognostic stratification and shows better trial-level surrogacy for overall survival compared with mRECIST-based progression-free survival. Pending prospective validation, ARTIMES could potentially facilitate a more reliable response evaluation in pleural mesothelioma. FUNDING: Asbestos-Related Disease Section (SAGA) of the Dutch Society of Pulmonology and Tuberculosis (NVALT), Dutch Cancer Society, and Dutch Ministry of Health, Welfare and Sport.
引用
- Lipman KBWG, Wittenberg R, de Oliveira Taveira M, et al. Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study. Lancet Oncol. 2026. PMID: 42309108. doi:10.1016/S1470-2045(26)00084-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。